Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference

Results from three clinical studies show ecnoglutide to be safe and well-tolerated, and demonstrate robust therapeutic effects in overweight/obese and type 2 diabetes patients On-going Phase 3 clinical trials in Chinese patients with type 2 diabetes and obesity have achieved target…